16/04/2018 14:17:17

Novo Nordisk A/S - Share repurchase programme

Related content
09 Apr - 
Novo Nordisk A/S - Share repurchase programme
03 Apr - 
Status regarding Novo Nordisk's holding of its own shar..
03 Apr - 
Novo Nordisk A/S - Share repurchase programme
Related debate
19 Apr - 
https://www.nordnet.dk/mux/web/marknaden/aktiehemsidan/..
19 Apr - 
@Jahat Hvordan ved du, at du ikke faar placebo? Er det ..
19 Apr - 
Jeg er af testpersonerne i fedmestudiet af Novos semagl..

Bagsværd, Denmark, 16 April 2018 - On 5 February 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14 billion to be executed during a 12-month period beginning 1 February 2018.

Under the programme initiated 5 February 2018, Novo Nordisk will repurchase B shares for an amount up to DKK 2.5 billion in the period from 6 February 2018 to 30 April 2018.

Further information

Media:

 

 

Anne Margrethe Hauge +45 4442 3450

amhg@novonordisk.com

Ken Inchausti (US) +1 609 786 8316

kiau@novonordisk.com

 

 

 

Investors:

 

 
Peter Hugreffe Ankersen +45 3075 9085

phak@novonordisk.com

Anders Mikkelsen +45 3079 4461

armk@novonordisk.com

Christina Kjær +45 3079 3009

cnje@novonordisk.com

Company Announcement No 32 / 2018

CA20180416 Safe Harbour CA_UK


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Apr
NOVO-B
Novo får godkendt kombinationsprodukt i Canada   Novo Nordisk har fået en godkendelse fra de canadis..
5
18 Apr
NOVO-B
At hvile på laurbærrene gjorde Sanofi, med Lantus, de havde ikke noget at sætte i stedet (Toujeo afl..
5
18 Apr
NOVO-B
Vi ved allerede fra tidlere tråde at Ozempic allerede i uge 4-5 var bedre end de seneste og gamle GL..
5
18 Apr
NOVO-B
Ca 85% af Novo's omsætning er superior og langt foran konkurrenterne. Det er i det lys, du skal vurd..
4
19 Apr
NOVO-B
@J-D. Du skriver - "den skal tage sig sammen". Jeg mener nu nærmere at det er på de bonede gulve i B..
3
18 Apr
NOVO-B
Nej, det ved jeg, at Ozempic ikke vil, i kritisk grad.   Det er forskellige patientgrupper, og Victo..
3
18 Apr
NOVO-B
Er Mr. Nada der nu igen, har du opdaget at jeg har ½veret i 293 og købt Jyske i 359,90   kan du selv..
3
18 Apr
NOVO-B
Det hjælper med gode suppleringspriser ;)
3
18 Apr
NOVO-B
"Men fortæl gerne hvorfor du mener semaglutid vil "smadre alle konkurrenter på volumen og skabe klar..
3
16 Apr
NOVO-B
Novo steg da idag. Det kan meget ofte betale sig at købe en pæn portion Novo aktier i lukkeauktionen..
3

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer
2
Leading Petroleum Industry Engineer and Researcher Joins Stamper Oil and Gas Technical Advisory Board
3
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
4
Brookfield Residential’s Stunning New Agave Neighborhood to Debut Soon at Spencer’s Crossing in Murrieta
5
Urban Airship Names Michael Stone as Senior Vice President of Marketing

Related stock quotes

Novo Nordisk B A/S 287.55 -1.9% Stock price decreasing
Novo Nordisk 46.89 -1.3% Stock price decreasing

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
20 April 2018 05:41:51
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180417.1 - EUROWEB1 - 2018-04-20 06:41:51 - 2018-04-20 05:41:51 - 1000 - Website: OKAY